2.08

0.48% 0.01

Mural Oncology Plc (MURA)

Overview News Price History Discussions Forecast

Mural Oncology Plc stock is traded at $2.08, with a volume of 435.37K. It is up +0.48% in the last 24 hours and down -15.10% over the past month. Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Previous Close:

$2.07

Open:

$2.07

24h Volume:

435.37K

Relative Volume:

2.15

Market Cap:

$36.03M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+18.18%

1M Performance:

-15.10%

6M Performance:

-48.64%

1Y Performance:

-36.59%

1-Day Range:

$2.07

$2.08

1-Week Range:

$1.76

$2.09

52-Week Range:

$0.95

$4.74

Mural Oncology Plc Stock (MURA) Company Profile

Name

Mural Oncology Plc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

353 1 905 8020

Address

10 EARLSFORT TERRACE, DUBLIN 2

Employee

116

Twitter

Next Earnings Date

2025-05-20

Latest SEC Filings

MURA's Discussions on Twitter

Compare MURA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MURA Mural Oncology Plc	2.08	31.53M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Mural Oncology Plc Stock (MURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-25-25	Downgrade	Raymond James	Strong Buy → Outperform
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Apr-04-24	Initiated	Morgan Stanley	Overweight

Mural Oncology Plc (MURA)

Mural Oncology Plc Stock (MURA) Company Profile

Compare MURA with other stocks

Mural Oncology Plc Stock (MURA) Upgrades & Downgrades

Mural Oncology Plc Stock (MURA) Latest News

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive

MURA’s Unexpected Surge: Analyzing Stock Movement - StocksToTrade

Mural Oncology to be Acquired by XRA 5 - citybiz

XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million. - MarketScreener

Mural Oncology To Be Acquired By XOMA Royalty - MSN

Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP

After culling 90% of staff, Waltham biotech finds buyer - NBC Boston

MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders - MarketScreener

Form 8.3Mural Oncology plc - Business Wire

Citadel Group discloses 1.44% stake in Mural Oncology - Investing.com

Mural Jumps on Partnership with XOMA - Baystreet.ca

XOMA Royalty To Acquire Mural Oncology - Nasdaq

Mural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cash - TipRanks

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - The Manila Times

XOMA Royalty Unit to Acquire Mural Oncology - MarketScreener

XOMA Royalty to acquire Mural Oncology for up to $2.24 per share - Investing.com

Mural Oncology Announces Entry into Agreement to be - GlobeNewswire

WALTHAM, DUBLIN, EMERYVILLEMural Oncology agrees to acquisition by XOMA Royalty subsidiary - Investing.com

98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal - Stock Titan

Mural Oncology plc Enters Reversal Setup in Weekly ChartsQuarterly Performance Summary & Community Supported Trade Ideas - newsyoung.net

Risk adjusted return profile for Mural Oncology plc analyzedWeekly Risk Summary & Weekly Watchlist for Hot Stocks - Newser

Candlestick signals on Mural Oncology plc stock today2025 Macro Impact & Daily Entry Point Trade Alerts - Newser

Tick level data insight on Mural Oncology plc volatilityShort Setup & Smart Swing Trading Alerts - Newser

Understanding Mural Oncology plc’s price movementJuly 2025 Action & Fast Entry and Exit Trade Plans - Newser

Using flow based indicators on Mural Oncology plcInsider Buying & Safe Capital Investment Plans - Newser

Citadel Group discloses 1.53% stake in Mural Oncology - Investing.com India

Mass. biotech company cuts 90% of workforce - MSN

Citadel Group discloses 1.53% stake in Mural Oncology By Investing.com - Investing.com South Africa

Visual analytics tools that track Mural Oncology plc performanceTreasury Yields & Fast Exit and Entry Trade Guides - Newser

Multi factor analysis applied to Mural Oncology plcWeekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - Newser

Smart tools for monitoring Mural Oncology plc’s price action2025 Trading Volume Trends & Real-Time Volume Spike Alerts - Newser

Is Mural Oncology plc meeting your algorithmic filter criteriaPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser

What technical models suggest about Mural Oncology plc’s comebackInflation Watch & Community Shared Stock Ideas - Newser

Will breakout in Mural Oncology plc lead to full recoveryM&A Rumor & Technical Entry and Exit Alerts - Newser

Will Mural Oncology plc be affected by tariffsQuarterly Performance Summary & Free Safe Capital Growth Stock Tips - sisa-n.com

Can you recover from losses in Mural Oncology plcJuly 2025 Opening Moves & Intraday High Probability Alerts - Newser

Sentiment analysis tools applied to Mural Oncology plcJuly 2025 Outlook & Intraday High Probability Setup Alerts - Newser

Chart based analysis of Mural Oncology plc trendsTrade Risk Summary & Weekly High Return Stock Opportunities - Newser

Citadel Group discloses 1.58% stake in Mural Oncology By Investing.com - Investing.com Canada

Citadel Group discloses 1.58% stake in Mural Oncology - Investing.com

Will Mural Oncology plc Stock Benefit from AI and Green Energy Trends2025 Technical Patterns & Free Community Consensus Stock Picks - Newser

AI Tools Suggest Mural Oncology plc May Outperform This WeekVolume Spike & AI Powered Trade Plan Recommendations - beatles.ru

Mural Oncology shares rise 5.59% premarket after Vanguard Group, Inc. disclosed a position in the company. - AInvest

Sector ETF Data Correlates with Strength in Mural Oncology plcJuly 2025 Highlights & Proven Capital Preservation Methods - beatles.ru

Is Mural Oncology plc a strong candidate for buy and hold2025 Volatility Report & Verified Momentum Stock Ideas - classian.co.kr

Mural Oncology shares rise 1.81% premarket after Vanguard Group, Inc. disclosed a position in the company. - AInvest

Citadel Group discloses 1.17% stake in Mural Oncology By Investing.com - Investing.com India

Is Mural Oncology plc Stock Overbought or Oversold RSI Indicator AnalysisHigh Probability Trade Plan with Indicators - Newser

Mural Oncology Plc Stock (MURA) Financials Data

Revenue

Net Income

Cash Flow

EPS

Mural Oncology Plc Stock (MURA) Insider Trading

Similar to MURA